Tango Therapeutics (TNGX) Starts A Phase 1 Or 2 Trial, Is The 54% Undervalued View Justified?
Tango Therapeutics (TNGX) moved into focus after announcing a Phase 1/2 trial that pairs its oral PRMT5 inhibitor vopimetostat with Erasca’s pan RAS molecular glue ERAS-0015 in specific MTAP-deleted cancers.
The latest Phase 1/2 combination trial lands after a powerful run for Tango Therapeutics, with a year-to-date share price return of about 141% and a 1-year total shareholder return of roughly 173%. At the same time, the 90-day share price return has fallen about 22% and shorter term moves remain choppy, suggesting that momentum has cooled recently while longer term holders still sit on substantial gains.
Scan a curated set of oncology-focused opportunities by comparing Tango Therapeutics with 35 healthcare AI stocks that are also developing treatments for hard-to-treat diseases.
Tango Therapeutics now carries a multi billion dollar valuation after a sharp rally and a recent pullback. Do the current numbers still leave enough potential upside to justify the clinical and execution risk, or not?
Most Popular Narrative: 54% Undervalued
Tango Therapeutics closed at $21.50 compared with a narrative fair value of $47.09, so the current price sits well below what that framework implies and places significant emphasis on whether its lead oncology program can support the overall investment case.
The main thing that has to go right is for vopimetostat based regimens, including RAS inhibitor combinations, to convert strong response and PFS data into successful late-stage trials in competitive indications such as pancreatic cancer.
The current valuation, including a stock price that has risen around 7 to 8 times over the past year alongside multiple Buy or Overweight ratings and higher price targets, implies that the market is pricing in meaningful commercial potential for the vopimetostat franchise.
See why 2 investors see Tango Therapeutics as 54% undervalued.
Result: Fair Value of $47.09 (UNDERVALUED)
Still, Tango Therapeutics leans heavily on vopimetostat and TNG456, so any weak data or regulatory setbacks could quickly challenge the view that the shares are underpriced.
Find out about the key risks to this Tango Therapeutics narrative.
Another View On Tango Therapeutics' Valuation
The narrative fair value of $47.09 presents Tango Therapeutics as underpriced. The P/B ratio tells a different story. At 3.5x book compared with 1.8x for the wider US biotech group and 6x for peers, the stock is neither cheap nor extreme. Does that mixed signal make you more cautious or more curious about the upside risk?
For a closer look at how this pricing compares with fundamentals, review the valuation breakdown in the See what the numbers say about this price — find out in our valuation breakdown..
Next Steps
Mixed signals on Tango Therapeutics so far. If you want to move quickly instead of watching from the sidelines, start by weighing the 1 key reward and 3 important warning signs.
Ready For More Investment Ideas Beyond Tango Therapeutics?
Do not stop with a single story. Broaden your opportunity set with focused stock lists that surface clear traits, from value potential to balance sheet strength and income resilience.
- Target potential upside by scanning a curated group of quality companies trading below their estimated worth through the 38 high quality undervalued stocks.
- Prioritize resilience first by tracking businesses that pass strict balance sheet checks using the list of solid balance sheet and fundamentals (25 results).
- Build an income stream by reviewing financially stronger payers highlighted in the 7 dividend fortresses.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com